Bach2 is a lymphoid-specific transcription factor with a prominent role in B-cell development and apoptosis-induction in response to oxidative stress. We previously showed that Bach2 is downregulated in chronic myeloid leukaemia (CML), and here we demonstrate the mechanism by which Bcr-Abl mediates this phenomenon. We have cloned a 3.9 Kb genomic DNA fragment upstream of the transcription initiation site, and delineated the core and proximal BACH2 promoter regions. Transient BCR-ABL expression led to significant reduction in BACH2 promoter activity and this effect was dependent on the kinase function of the oncoprotein. Sequential deletions disclosed several regulatory elements within the promoter region, as well as within BACH2 exonic sequences. Analysis of these elements and transient transfection assays led to the identification of the Pax5 transcription factor as a potent trans-activator of BACH2, whose effect is predominantly mediated through occupation of a binding site on the BACH2 promoter, as demonstrated by both in vitro and in vivo experiments. Overall, our data show that Pax5 functions as an intermediate effector in the Bcr-Abl-mediated transcriptional repression of BACH2. The current results, combined with previous reports, establish Pax5 and Bach2 as transcriptional targets of Bcr-Abl, whose downregulation may contribute to lymphoid blast crisis of CML.
INTRODUCTION
Chronic myeloid leukaemia (CML) is consistently associated with the t(9;22)(q34;q11) chromosomal translocation, which generates a BCR-ABL fusion gene on the Philadelphia (Ph) chromosome, encoding the constitutively active tyrosine kinase p210
Bcr-Abl . 1 CML classically evolves in three clinical stages: chronic phase (CP), accelerated phase and blast crisis (BC). Progress to the advanced stages is characterised by an accumulation of immature blasts in the bone marrow and increased genomic instability. 2, 3 The transformed clone in BC is, in the majority of cases, of myeloid or, less frequently, of B-lymphoid cell lineage. 4 Despite increasing knowledge about a variety of additional genetic lesions in BC of CML, it is still unclear how these lesions originate and which factors determine transformation of myeloid or lymphoid nature. Inhibition of apoptosis, a prominent feature of Bcr-Abl oncogenicity, 5 could facilitate the accumulation of mutations and DNA mis-repair 6, 7 which, in normal cells, would result in cell death. In addition, deregulated expression of key B-lymphoid development genes could contribute to the emergence of a transformed clone in lymphoid BC.
The association between BACH2 and CML was uncovered when genes exemplified by BACH2, cyclin D2 and BCL-6 were identified as being transcriptionally regulated by Bcr-Abl. [8] [9] [10] The lymphoidspecific 11, 12 transcription factor Bach2 functions as a homoor a heterodimer partner of the small Maf proteins (MafK, MafF, MafG). 11 It acts predominantly as a transcription repressor, 11 controlling processes such as the induction of apoptosis in response to oxidative stress. 13 In B-lymphoid development, Bach2 negatively regulates the immunoglobulin heavy chain (IgH) gene 3 0 -enhancer 12 and is instrumental for class switch recombination and somatic hypermutation of Ig genes, with effects on AID, Blimp-1 and XBP-1 gene expression. 14 We have previously described that Bcr-Abl not only downregulates BACH2 expression, 10 but also inhibits its nuclear translocation through serine phosphorylation via the PI-3 K/S6K pathway, suppressing, as a consequence, Bach2 pro-apoptotic function. 15 Those findings are consistent with a Bach2 role as tumour suppressor gene.
Pax5 (also known as BSAP) is a prominent B-lymphoid transcription factor. Like Bach2, its expression pattern is differentiation stage-dependent, strictly regulated and reminiscent of its role in B-lymphoid lineage commitment, where it fulfills a dual function by repressing alternative lineage genes while simultaneously activating B-cell-specific genes (reviewed in Cobaleda et al. 16 ). In addition, Pax5 influences processes taking place at late stages of B-cell differentiation, such as the control of B-cell proliferation, 17 IgH class switch 18 and suppression of plasma cell differentiation. 19 In this study, we demonstrate that BACH2 is transcriptionally repressed by Bcr-Abl, and identify Pax5 as a potent trans-activator of BACH2, whose effect is mediated through direct binding to a site on the BACH2 promoter. Furthermore, we show that the expression profile of Pax5 in primary cells and CML cell lines parallels that of BACH2, supporting the possibility of an association between disrupted expression of both the genes and CML disease development.
MATERIALS AND METHODS
Standard methods for cell culture, retroviral infection, rapid amplification of cDNA ends, real-time quantitative PCR and western blot analysis are described in the Supplementary Information.
Luciferase reporter constructs
The luciferase reporters pGL3/BACH2P3912, pGL3/BACH2P3003, pGL3/ BACH2P1605, pGL3/BACH2P725, pGL3/BACH2P184, pGL3/BACH2P126 and pGL3/BACH2P11 þ , were constructed through PCR amplification of the corresponding BACH2 5 0 -regions to the end of exon 1 from normal leukocyte DNA, followed by restriction enzyme digestion and ligation into the pGL3-basic vector. For the pGL3/BACH2P72 þ construct two complementary oligonucleotides were designed spanning the sequence from 72 nucleotides downstream of the transcription initiation site (TIS) of BACH2, to the end of exon 1 (Supplementary Figure 1) and ligated into pGL3-basic. The remaining reporter constructs, namely pGL3/BACH2P649, pGL3/BACH2P640, pGL3/BACH2P568, pGL3/BACH2P521 and pGL3/BACH-2P261, were generated using the TaKaRa deletion kit for kilo-sequencing (TaKaRa, Kyoto, Japan). All constructs were checked for mutations by sequencing.
Luciferase assays
The cell line 697 was transfected using FUGENE6 (Roche, Penzberg, Germany), following the manufacturer's instructions. BV173 cells were electroporated as described previously. 20 Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). All results were normalised against the luciferase activity of the control pEF-sea pansy plasmid. Nonparametric Mann-Whitney test was used for statistical analysis.
Electrophoretic mobility shift assay Nuclear proteins were prepared as described previously. 21 The doublestranded probe, corresponding to a specific sequence on the BACH2 promoter (Supplementary Figure 1) was 5 0 -labelled with g-
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P. Each 20 ml of binding reaction contained 3 mg of nuclear protein extract, 2 mg poly (deoxyinosinic-deoxycytidylic) (GE, Fairfield, CT, USA), 15 000-25 000 counts per minute of purified labelled probe and 5 ml of 70% glycerol, in 1 Â binding buffer. 22 Probe binding was detected by autoradiography on Kodak-X-OMAT AR (Sigma, St Louis, MO, USA).
Chromatin immunoprecipitation (ChIP)
Chromatin fixation, purification and immunoprecipitation were done as previously described. 23 Immunoprecipitation was performed using 2-5 mg of antibody or normal rabbit or goat (Sigma) serum. The precipitated DNA was used as template for PCR with primers spanning the regions of interest on the BACH2, CD19 (positive control) and KRAS (negative control) promoters. Input DNA, fixed and sonicated but not subjected to immunoprecipitation, was used as positive control.
RESULTS
We first confirmed that Bach2 levels are downregulated by Bcr-Abl by ectopically expressing the fusion oncogene in the Ph-negative lymphoid cell line 697, and demonstrated that either degradation of Bcr-Abl or inhibition of its tyrosine kinase activity are able to reverse the oncoprotein effect on Bach2 expression (Supplementary Figure 2 ).
Cloning and characterisation of the BACH2 promoter Next, the BACH2 TIS was identified by 5 0 -rapid amplification of cDNA ends PCR as a G nucleotide on exon 1, located 601 bp upstream the ATG codon on exon 6 (Supplementary Figure 1) . The BACH2 proximal promoter was cloned and characterised by engineering several DNA constructs encompassing sequences 5 0 of BACH2 exon 1, and cloning them into pGL3. The full range of reporter constructs was transiently transfected into 697 cells and the highest increase in luciferase activity was observed with the pGL3/BACH2P725 reporter construct (Figure 1 ), suggesting that maximum BACH2 promoter activity is retained within 725 nucleotides upstream of the TIS. A series of progressive deletions within this region led to gradual and significant (po0.05) decrease in reporter activity, and highlighted the regulatory importance of two regions of the BACH2 promoter, À 725/ À 568 and À 126/ þ 72 ( Figure 1 ).
Repressive effect of Bcr-Abl on BACH2 promoter activity Co-transfection of BCR-ABL with the pGL3/BACH2P725 promoter reporter in 697 cells led to B60% downregulation in BACH2 promoter activity (Figure 2a ). This effect was dependent on the kinase activity of the oncoprotein, as treatment for 24 h with imatinib (IM) led to complete reconstitution of promoter activity in a dose-dependent manner ( Figure 2a ). The dependence of the Bcr-Abl-mediated effect on its kinase activity was also demonstrated by co-transfection of pGL3/BACH2P725 with a kinase dead BCR-ABL construct, which produced no significant effect on the reporter activity ( Figure 2a experiments demonstrate that BACH2 is transcriptionally regulated by Bcr-Abl and that this regulation depends on the kinase activity of the oncoprotein.
We next analysed the regions in the BACH2 promoter necessary for Bcr-Abl control by co-transfecting 697 cells with BCR-ABL and reporter constructs containing different lengths of the BACH2 promoter. Co-expressing BCR-ABL with the majority of these the BACH2 TIS might be important for Bcr-Abl-mediated suppression of BACH2 transcription.
Bcr-Abl does not influence histone acetylation/methylation on the BACH2 promoter As histone modifications on gene promoters affect the gene expression, 24 we analysed the Bcr-Abl influence on histone acetylation or methylation patterns on two regions of the BACH2 promoter that prevailed for their regulatory importance, À 759/ À 483 and À 126/exon 1 (Figure 1 Figure 3) . Moreover, IM treatment appears to have no effect on histone modification on the BACH2 promoter.
BACH2 is a transcriptional target of Pax5
The previous results suggest that regulation of the BACH2 promoter is predominantly dependent on transcription factor binding. Therefore, we used MatInspector (http://www.genomatix. de/cgi-bin/matinspector_prof/mat_fam.pl) for prediction of transcription factor binding sites contained within À 725 bp from the TIS of BACH2. A candidate transcription factor thus identified was the B-cell differentiation factor Pax5, previously shown as being able to induce Bach2 expression in mouse pro-B cells. 25 Based on the conserved expression pattern between Bach2 and Pax5 proteins, as well as the functional implication of both in B-cell development, we investigated the possibility that Pax5 regulates BACH2 transcription in human cells.
The MatInspector analysis identified three potential Pax5-binding sites within -725 nucleotides from the BACH2 TIS (Supplementary Figures 4 and 5) . Therefore, we co-transfected 697 cells with the pSG5/Pax5 and the pGL3/BACH2P725 constructs and found that, indeed, ectopic PAX5 expression led to a 2.7-fold increase in BACH2 promoter activity (Figure 3a) .
In order to identify which of the three sites is responsible for the Pax5 effect we co-transfected 697 cells with a PAX5-expressing plasmid and reporter constructs devoid of regions containing Pax5-binding sites I ( À 559/ À 532), I and II ( À 458/ À 431) and I, II and III ( þ 15/ þ 42), respectively. Whereas Pax5 increased reporter activity in the absence of sites I and II, no induction in reporter activity was observed in the absence of site III (Figure 3a) . These experiments indicate that Pax5-binding site III ( þ 15/ þ 42) is essential for Pax5 regulation of BACH2 expression, and that sites I and II are dispensable for the Pax5 effect.
Pax5 binds to the BACH2 promoter both in vitro and in vivo Binding of Pax5 to site III ( þ 15/ þ 42) on the BACH2 promoter was investigated by electrophoretic mobility shift assay. When 697 nuclear extracts were incubated with a radiolabelled probe specific for the Pax5-binding site III ( þ 15/ þ 42), a single band was present (lane 2; Figure 3b) , suggesting Pax5 binding. The specificity of this binding was demonstrated by the absence of the band from lanes 1 (no nuclear extract) and 3 (competition with 100-fold excess unlabelled oligo). Incubation with the C-20 antibody, which recognises both Pax5a and Pax5b isoforms, Figure 3c) ; however, no immunoprecipitation of the region encompassing site I ( À 577/ À 550) occurred (lane 4, Figure 3c ). This experiment demonstrates in vivo binding of Pax5 to the BACH2 promoter at position þ 15/ þ 42.
Pax5 mediates BACH2 repression in CML cells
We noticed that the Pax5-binding site III ( þ 15/ þ 42) was within a region whose deletion reversed the suppressive effect of Bcr-Abl on BACH2 promoter activity (Figure 2c) . We therefore asked whether Bcr-Abl can suppress Pax5 expression in a manner similar to that seen for Bach2, and thus mediate BACH2 promoter repression through Pax5 downregulation.
Indeed, ectopic expression of BCR-ABL in 697 cells resulted in a twofold reduction of PAX5 mRNA levels, and treatment with IM completely rescued its expression (Figure 4a) , demonstrating that the Bcr-Abl kinase activity is responsible for the downregulation of PAX5. In addition, treatment of the lymphoid CML cell lines BV173 and TOM1 with IM induced an increase in BACH2 and PAX5 expression (Figure 4b ), whereas there was no noticeable increase in either mRNA when 697 (BCR-ABL-negative) and K562 (myeloid CML) cells were treated with IM. As expected, Pax5 and Bach2 protein expression was also induced after IM treatment of BV173 and TOM1 cells in a time-dependent manner (Figure 4c ). These results demonstrate that upon inhibition of Bcr-Abl by IM, evidenced by inhibition of phosphorylation of the Bcr-Abl specific target CRKL, Pax5 expression is increased in parallel with upregulation of Bach2 levels.
Moreover, analysis of mononuclear cells from patients with B-lymphoid BC of CML, although showing higher BACH2 and PAX5 expression than CP and myeloid BC of CML (as expected, as myeloid cells don't express either of these genes), showed significantly lower levels of BACH2 (Po0.0028) and PAX5 (Po0.0031) expression than the lineage correspondent cells from Ph-negative B-progenitor acute lymphoblastic leukaemia (B-ALL) patients (Figure 4d) .
Finally, we observed, by ChIP assay, low binding of Pax5 to the BACH2 promoter in BV173 cells and enhanced binding after the inhibition of Bcr-Abl by IM in a dose-dependent manner (Figure 4e) . The same IM dose-dependent increase in relative enrichment was observed for the Pax5 regulated gene CD19. This result suggests that inhibition of Pax5 expression by Bcr-Abl results in its decreased binding to the BACH2 promoter and, therefore, reduced BACH2 expression.
DISCUSSION
Transformation by the Bcr-Abl oncoprotein is mediated through activation of various signalling pathways, ultimately leading to the regulation of genes conferring the malignant phenotype of CML and Ph þ ALL.
1 Here, we demonstrate that BACH2 is an indirect transcriptional target of Bcr-Abl, and propose that the repressive effect on BACH2 expression is actively maintained, at least partly, via suppression of Pax5 expression.
The cloning of the BACH2 promoter and data from BCR-ABLoverexpression experiments demonstrate that BACH2's decreased expression is due to a Bcr-Abl-dependent effect on promoter activity, which is reversed by induced degradation of Bcr-Abl or inhibition of its kinase activity. A similar type of regulation was described for the pro-apoptotic factor Bim, where IM treatment induced accumulation of a trans-activator, FOXO3a, and its subsequent binding to the BIM promoter. 26 Subsequently, the IM-mediated transcriptional and posttranslational activation of Bim was suggested to have a major role in IM-induced apoptosis of BCR-ABL-transformed cells, 27 a phenomenon which is likely to also apply to the pro-apoptotic function of Bach2. 13 Our data do not exclude the possible existence of additional mechanisms of Bcr-Abl-mediated regulation of BACH2 expression, such as effects on enhancer elements, or on BACH2 mRNA stability, processing or nucleocytoplasmic shuttling. [28] [29] [30] [31] In fact, we have previously shown that even the little amount of Bach2 produced in Bcr-Abl-positive cells is constitutively serine-phosphorylated. 15 This prevents the translocation of Bach2 to the nucleus for trans-repression of its anti-apoptotic target genes, such as HO-1 which, as a consequence, is upregulated in CML. 15 Taken together, these data suggest that Bach2 is a crucial pro-apoptotic protein, which needs to be suppressed by all means by Bcr-Abl in order to ensure the latter's oncogenic activity.
We also investigated the possibility of Bcr-Abl-dependent epigenetic changes within the BACH2 promoter. Our ChIP data revealed, however, that the pattern of histone modifications on the BACH2 promoter in Bcr-Abl-positive cells is reminiscent of an accessible chromatin conformation, even though the BACH2 gene expression is repressed. Therefore, it is more likely that Bcr-Abl maintains low levels of BACH2 expression through the regulation of transcription factor expression and/or binding onto the BACH2
promoter. A similar model of regulation in the context of CML was proposed for cyclin D2. In the presence of Bcr-Abl, Stat5 binds to the promoter and activates transcription of cyclin D2, while upon IM treatment Stat5 is replaced by the Bcl-6 transcription repressor. 20 We thus hypothesised that, in a reverse fashion, BcrAbl may suppress BACH2 transcription by inhibiting the activity of BACH2 trans-activators, consequently allowing for putative repressive elements to suppress BACH2 expression ( Figure 5) .
Our experiments revealed that Pax5 binds to BACH2 exon 1 and induces BACH2 expression on human Bcr-Abl-positive and negative pro-B-cell lines. The presence of transcription factor binding sites within untranslated exonic sequences is not rare; an example is the PAX5 gene itself, which contains an important repressive element within the 5 0 -untranslated region of its alternative exon 1A. 32 Several lines of evidence support our finding of BACH2 as a transcriptional target of Pax5 in human pro-B cells. Firstly, Pax5 was found to bind to the BACH2 promoter and enhancer and to induce BACH2 expression in mouse pro-B cells. 25, 33 Secondly, both Bach2 and Pax5 are expressed from pro-B to mature B-cell stages. 12 In addition, Pax5 is known to confer transcriptional activation/repression through directly binding to the promoter or enhancer regions of several genes associated with B-cell development, 25 like BACH2 and IgH. Furthermore, our result showing that Pax5 induces BACH2 expression without changing chromatin conformation in Bcr-Ablpositive cells (Supplementary Figure 3) is also supported by a recent study demonstrating that BACH2 presented an active histone mark in PAX5 þ / þ murine pro-B cells, and deletion of Pax5 did not alter this chromatin status. 33 Although our data do not address specifically the issue of regulation of Bach2 transcription during B-cell differentiation, taken together with the evidence from the literature, 12, 25, 33 they could suggest a model in which during early stages of B-cell development Pax5 induces BACH2 transcription ( Figure 5 ).
Several studies have associated deregulated PAX5 expression with human cancer. [34] [35] [36] [37] [38] Chromosomal translocations have implicated PAX5 as an oncogene in a subset of B-ALL and nonHodgkin lymphomas (reviewed in Cobaleda et al. 16 ), with a subsequent demonstration that PAX5 fusions function as dominant-negative suppressors of Pax5. 39 Moreover, somatic mutations on PAX5 (including deletions, amplifications, mutations and translocations) are detected in over 30% childhood B-ALL 38 and adult Ph þ ALL. 37 Overall, these mutations result in reduced expression of Pax5, which consequently alters expression of its target genes, 40 suggesting that PAX5 deletion could contribute to leukemogenesis. 38 Here, we demonstrate that Pax5 expression is repressed in Bcr-Abl-positive cells, and this repression is reversed by IM treatment. More importantly, the parallel expression profiles of PAX5 and BACH2 in primary B-lymphoid BC of CML as compared with Ph-negative B-ALL cells indicate that their pattern of regulation is not an artefact of transfection systems or immortal cell lines. In agreement with our findings, microarray screens detected downregulation of both genes in Ph-positive B-ALL patients compared with Ph À negative B-ALL. 41, 42 Similarly, PAX5 expression was reported to be reduced in cells from lymphoid BC of CML compared with germinal centre normal counterpart B cells, 43 corroborating our results on the effect of Bcr-Abl on PAX5 expression in lymphoid cells. In addition, they reported a higher PAX5 expression in lymphoid BC than in CP of CML, as we observed here ( Figure 4d) ; however, such relative increase is only apparent when comparing PAX5 expression in the lymphoid BC cells with the myeloid CP cells as it reflects the natural silencing of the B-cell-specific gene in the myeloid lineage. Intriguingly, a study employing tissue microarrays and immunohistochemical analysis revealed increased PAX5 expression in 72% of early pre-B-ALL, 100% of CML in lymphoid BC, 50% of AML and 50% of mixed B-cell ALL and AML; 44 however, the number of cases investigated was small.
We postulate that the Bcr-Abl-dependent suppression of BACH2 expression is partly mediated through repression of Pax5 expression via a currently unknown mechanism. As a result, CML cells with decreased PAX5 and BACH2 expression may still be capable of committing to the B-lymphoid lineage, 45 but may be impaired at late, antigen-driven stages of B-cell development, and at increased risk of premature and/or deregulated IgH transcription. 12, 46 This may, in turn, lead to an increase in the frequency of IgH gene rearrangements, 14 which may also correlate with an increase in pathogenic translocations. 47, 48 CML cells carrying such translocations would avoid elimination due to an inherent resistance to apoptosis, 1 mediated in part by the suppression in Bach2 expression, 13 and eventually be responsible for progression to BC ( Figure 5 ). It is possible that the degree of Pax5 and Bach2 suppression by BCR-ABL correlates with the risk of lymphoid BC transformation, so that serial measurements of their levels of expression during CP may provide prognostic information. This is currently being addressed in a large prospective clinical trial.
Our results identify BACH2 and PAX5 as Bcr-Abl targets. Ultimately, a detailed knowledge of the role of Bach2 in the pathogenesis and evolution of Ph-positive leukaemias may lead to therapeutic strategies involving genetic/chemical manipulation of this transcription factor and/or its targets. The clinical relevance of such biological knowledge is exemplified by the finding that anticancer drugs that produce reactive oxygen species, such as etoposide, doxorubicin and cytarabine, and which facilitate nuclear accumulation and activation of Bach2, can act synergistically with IM treatment through manipulating the pro-apoptotic function of Bach2. 
